Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(11):1714–1718. doi: 10.1038/bjc.1996.620

In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.

H L McLeod 1, V G Brunton 1, N Eckardt 1, M J Lear 1, D J Robins 1, P Workman 1, M A Graham 1
PMCID: PMC2077212  PMID: 8956783

Abstract

Amplification and increased expression of many growth factor receptors, including the epidermal growth factor receptor (EGFR), has been observed in human tumours. One therapeutic strategy for overcoming EGF autocrine control of tumour growth is inhibition of EGFR protein tyrosine kinase (PTK). A series of low molecular weight molecules have been identified which inhibit the EGFR PTK in vitro and demonstrate antiproliferative activity against human cancer cell lines with high expression of EGFR. A significant growth delay in squamous cancer xenografts has been reported for one of these compounds, the tyrphostin RG13022. Based on these encouraging results, we sought to confirm the activity of RG13022 in vivo and relate the effects to the in vivo plasma disposition. RG13022 and three additional peaks were detected by HPLC following intraperitoneal administration of 20 mg kg-1 RG13022 in MF1 nu/nu mice. RG13022 demonstrated rapid biexponential elimination from plasma with a terminal half-life of 50.4 min. RG13022 plasma concentrations were less than 1 microM by 20 min post injection. A primary product was identified as the geometrical isomer (E)-RG13022. Both RG13022 and its geometrical isomer inhibited DNA synthesis in HN5 cells after a 24 h in vitro incubation (IC50 = 11 microM and 38 microM respectively). Neither RG13022 nor its geometrical isomer displayed significant cytotoxicity. RG13022 had no influence on the growth of HN5 tumours when administered chronically, starting either on the day of tumour inoculation or after establishment of tumour xenografts. The rapid in vivo elimination of RG13022 has potential significance to the development of this and other related tyrphostin tyrosine kinase inhibitors, as plasma concentrations fell below that required for in vitro activity by 20 min post injection. The lack of in vivo tumour growth delay suggests that a more optimal administration schedule for RG13022 would include more frequent injections or continuous administration. An improved formulation for RG13022 is therefore required before further development of this or other similar protein tyrosine kinase inhibitors can be made. Alternative strategies should also be sought which display longer lasting in vivo exposures.

Full text

PDF
1714

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaronson S. A. Growth factors and cancer. Science. 1991 Nov 22;254(5035):1146–1153. doi: 10.1126/science.1659742. [DOI] [PubMed] [Google Scholar]
  2. Bartlett J. M., Langdon S. P., Simpson B. J., Stewart M., Katsaros D., Sismondi P., Love S., Scott W. N., Williams A. R., Lessells A. M. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 1996 Feb;73(3):301–306. doi: 10.1038/bjc.1996.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brunton V. G., Lear M. J., Robins D. J., Williamson S., Workman P. Synthesis and antiproliferative activity of tyrphostins containing heteroaromatic moieties. Anticancer Drug Des. 1994 Aug;9(4):291–309. [PubMed] [Google Scholar]
  4. Brunton V. G., Workman P. Cell-signaling targets for antitumour drug development. Cancer Chemother Pharmacol. 1993;32(1):1–19. doi: 10.1007/BF00685870. [DOI] [PubMed] [Google Scholar]
  5. Chakrabarty S., Rajagopal S., Huang S. Expression of antisense epidermal growth factor receptor RNA downmodulates the malignant behavior of human colon cancer cells. Clin Exp Metastasis. 1995 May;13(3):191–195. doi: 10.1007/BF00132207. [DOI] [PubMed] [Google Scholar]
  6. Dvir A., Milner Y., Chomsky O., Gilon C., Gazit A., Levitzki A. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J Cell Biol. 1991 May;113(4):857–865. doi: 10.1083/jcb.113.4.857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993 Oct 1;53(19):4637–4642. [PubMed] [Google Scholar]
  8. Fry D. W., Kraker A. J., McMichael A., Ambroso L. A., Nelson J. M., Leopold W. R., Connors R. W., Bridges A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093–1095. doi: 10.1126/science.8066447. [DOI] [PubMed] [Google Scholar]
  9. Harris A. L. The epidermal growth factor receptor as a target for therapy. Cancer Cells. 1990 Oct;2(10):321–323. [PubMed] [Google Scholar]
  10. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995 Mar 24;267(5205):1782–1788. doi: 10.1126/science.7892601. [DOI] [PubMed] [Google Scholar]
  11. Levitzki A. Tyrphostins--potential antiproliferative agents and novel molecular tools. Biochem Pharmacol. 1990 Sep 1;40(5):913–918. doi: 10.1016/0006-2952(90)90474-y. [DOI] [PubMed] [Google Scholar]
  12. Mendelsohn J. The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol. 1990 Oct;1(5):339–344. [PubMed] [Google Scholar]
  13. Modjtahedi H., Eccles S., Box G., Styles J., Dean C. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer. 1993 Feb;67(2):254–261. doi: 10.1038/bjc.1993.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Moroni M. C., Willingham M. C., Beguinot L. EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J Biol Chem. 1992 Feb 5;267(4):2714–2722. [PubMed] [Google Scholar]
  15. Plumb J. A., Milroy R., Kaye S. B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989 Aug 15;49(16):4435–4440. [PubMed] [Google Scholar]
  16. Ramdas L., McMurray J. S., Budde R. J. The degree of inhibition of protein tyrosine kinase activity by tyrphostin 23 and 25 is related to their instability. Cancer Res. 1994 Feb 15;54(4):867–869. [PubMed] [Google Scholar]
  17. Reddy K. B., Mangold G. L., Tandon A. K., Yoneda T., Mundy G. R., Zilberstein A., Osborne C. K. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 1;52(13):3636–3641. [PubMed] [Google Scholar]
  18. Stern D. F., Hare D. L., Cecchini M. A., Weinberg R. A. Construction of a novel oncogene based on synthetic sequences encoding epidermal growth factor. Science. 1987 Jan 16;235(4786):321–324. doi: 10.1126/science.3492043. [DOI] [PubMed] [Google Scholar]
  19. Traxler P., Trinks U., Buchdunger E., Mett H., Meyer T., Müller M., Regenass U., Rösel J., Lydon N. [(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase. J Med Chem. 1995 Jun 23;38(13):2441–2448. doi: 10.1021/jm00013a020. [DOI] [PubMed] [Google Scholar]
  20. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990 Apr 20;61(2):203–212. doi: 10.1016/0092-8674(90)90801-k. [DOI] [PubMed] [Google Scholar]
  21. Ward W. H., Cook P. N., Slater A. M., Davies D. H., Holdgate G. A., Green L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol. 1994 Aug 17;48(4):659–666. doi: 10.1016/0006-2952(94)90042-6. [DOI] [PubMed] [Google Scholar]
  22. Workman P., Brunton V. G., Robins D. J. Tyrosine kinase inhibitors. Semin Cancer Biol. 1992 Dec;3(6):369–381. [PubMed] [Google Scholar]
  23. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]
  24. Yoneda T., Lyall R. M., Alsina M. M., Persons P. E., Spada A. P., Levitzki A., Zilberstein A., Mundy G. R. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 1991 Aug 15;51(16):4430–4435. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES